This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/pdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/kegg-compound/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/drugbank/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00168/identifier/pharmgkb/

Statements

Subject Item
n2:DB00168
rdf:type
n3:Drug
n3:description
Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid. [PubChem]
n3:group
approved nutraceutical
n3:halfLife
At room temperature, aspartame is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7 however, its half-life is only a few days.
n3:indication
Used as a diet supplement and sugar substitute.
owl:sameAs
n15:DB00168 n18:DB00168
dcterms:title
Aspartame
adms:identifier
n5:2877 n7:DB00168 n10:PME n11:PA448493 n12:C11045 n13:D02381 n17:Aspartame
n3:mechanismOfAction
180 to 200 times sweeter than sucrose, it is metabolized as a protein and its subsequent amino-acids used up in there respective mechanisms.
n3:packager
n16:271B4FF5-363D-11E5-9242-09173F13E4C5
n3:synonym
Aspartam L-Aspartyl-L-phenylalanine methyl ester Aspartamo Asp-phe-ome 1-methyl N-L-α-aspartyl-L-phenylalanate 1-Methyl N-L-alpha-aspartyl-L-phenylalanine 3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester Aspartamum Aspartame 3-Amino-N-(alpha-methoxycarbonylphenethyl) succinamic acid Aspartylphenylalanine methyl ester 3-Amino-N-(α-methoxycarbonylphenethyl) succinamic acid 1-Methyl N-L-alpha-aspartyl-L-phenylalanate 3-Amino-N-(α-carboxyphenethyl)succinamic acid N-methyl ester
n3:toxicity
Mild gastrointestinal side effects including diarrhea have been reported.
n3:synthesisReference
Josef Tsau, "Convenient to use aspartame and method of making." U.S. Patent US5582351, issued August, 1972.
n19:hasConcept
n20:M0001821
n3:IUPAC-Name
n6:271B4FFB-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5001-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5000-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4FFD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4FFE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4FFF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5011-363D-11E5-9242-09173F13E4C5 n6:271B4FF9-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5013-363D-11E5-9242-09173F13E4C5 n6:271B4FF7-363D-11E5-9242-09173F13E4C5 n6:271B4FFA-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B4FF8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B5007-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5008-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5002-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5003-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5005-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5004-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5006-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed in the small intestine, aspartame is metabolized and absorbed very quickly.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
22839-47-0
n3:category
n3:containedIn
n9:271B4FF6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B500D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B500F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5010-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5012-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B500C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B500B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B500E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4FFC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B5009-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B500A-363D-11E5-9242-09173F13E4C5